

1 **Sequence Analysis of 20,453 SARS-CoV-2 Genomes from the Houston**  
2 **Metropolitan Area Identifies the Emergence and Widespread**  
3 **Distribution of Multiple Isolates of All Major Variants of Concern**

4  
5 S. Wesley Long,<sup>a,b,1</sup> Randall J. Olsen,<sup>a,b,1</sup> Paul A. Christensen,<sup>a</sup> Sishir Subedi,<sup>a</sup> Robert Olson,<sup>c,d</sup>  
6 James J. Davis,<sup>c,d</sup> Matthew Ojeda Saavedra,<sup>a</sup> Prasanti Yerramilli,<sup>a</sup> Layne Pruitt,<sup>a</sup> Kristina  
7 Reppond,<sup>a</sup> Madison N. Shyer,<sup>a</sup> Jessica Cambric,<sup>a</sup> Ilya J. Finkelstein,<sup>e</sup> Jimmy Gollihar,<sup>a,f</sup> and  
8 James M. Musser<sup>a,b#</sup>

9  
10 *From the <sup>a</sup>Center for Molecular and Translational Human Infectious Diseases Research,*  
11 *Department of Pathology and Genomic Medicine, Houston Methodist Research Institute and*  
12 *Houston Methodist Hospital, 6565 Fannin Street, Houston, Texas, 77030*

13 *<sup>b</sup> Departments of Pathology and Laboratory Medicine, and Microbiology and Immunology, Weill*  
14 *Cornell Medical College, 1300 York Avenue, New York, New York, 10065*

15 *<sup>c</sup> Consortium for Advanced Science and Engineering, 22 University of Chicago, 5801 South Ellis*  
16 *Avenue, Chicago, Illinois, 60637*

17 *<sup>d</sup> Computing, Environment and Life Sciences, Argonne National Laboratory, 9700 South Cass*  
18 *Avenue, Lemont, Illinois, 60439*

19 *<sup>e</sup> Department of Molecular Biosciences and Institute of Molecular Biosciences, The University of*  
20 *Texas at Austin, Austin, Texas 78712*

21 *<sup>f</sup> CCDC Army Research Laboratory-South, University of Texas, Austin, Texas 78712*

22

23 Number of text pages: 12

24 Number of tables: 1

25 Number of figures: 2

26 Running head (40 characters or less): SARS-CoV-2 variants of concern in Houston, TX

27

28 # Address correspondence to James M. Musser, M.D., Ph.D., Department of Pathology and

29 Genomic Medicine, Houston Methodist Research Institute, 6565 Fannin Street, Suite B490,

30 Houston, Texas 77030. Tel: 713.441.5890, E-mail: [jmmusser@houstonmethodist.org](mailto:jmmusser@houstonmethodist.org).

31

32 Disclosures: None.

33

34

35

36

37

38

39

40

41

42

43

44 [Abstract (220 words)]

45 Since the beginning of the SARS-CoV-2 pandemic, there has been international concern about  
46 the emergence of virus variants with mutations that increase transmissibility, enhance escape  
47 from the human immune response, or otherwise alter biologically important phenotypes. In  
48 late 2020, several “variants of concern” emerged globally, including the UK variant (B.1.1.7),  
49 South Africa variant (B.1.351), Brazil variants (P.1 and P.2), and two related California “variants  
50 of interest” (B.1.429 and B.1.427). These variants are believed to have enhanced  
51 transmissibility capacity. For the South Africa and Brazil variants, there is evidence that  
52 mutations in spike protein permit it to escape from some vaccines and therapeutic monoclonal  
53 antibodies. Based on our extensive genome sequencing program involving 20,453 virus  
54 specimens from COVID-19 patients dating from March 2020, we report identification of all  
55 important SARS-CoV-2 variants among Houston Methodist Hospital patients residing in the  
56 greater metropolitan area. Although these variants are currently at relatively low frequency in  
57 the population, they are geographically widespread. Houston is the first city in the United  
58 States to have all variants documented by genome sequencing. As vaccine deployment  
59 accelerates worldwide, increased genomic surveillance of SARS-CoV-2 is essential to  
60 understanding the presence and frequency of consequential variants and their patterns and  
61 trajectory of dissemination. This information is critical for medical and public health efforts to  
62 effectively address and mitigate this global crisis.

63

64

65 [Introduction]

66 The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of  
67 coronavirus disease 2019 (COVID-19). Since first being identified in December 2019,<sup>1-4</sup> the virus  
68 has spread globally and is responsible for massive human morbidity and mortality worldwide.<sup>5-9</sup>  
69 At the onset of the pandemic, effective treatments for COVID-19 were lacking. But as a result of  
70 intense global research efforts, monoclonal antibody (mAbs) therapies<sup>10, 11</sup> and several  
71 vaccines,<sup>12, 13</sup> primarily directed against the spike protein, have been developed to treat and  
72 prevent SARS-CoV-2 infection.

73 In late 2020 the international research community described several SARS-CoV-2  
74 “variants of concern” that warranted special scrutiny. These include the United Kingdom (UK)  
75 variant (B.1.1.7), South Africa variant (B.1.351), Brazil variants (P.1 and P.2) and two California  
76 variants (B.1.429/CAL.20C and B.1.427/CAL.20C).<sup>14-22</sup> These virus variants were designated as  
77 “concerning” predominantly due to their reported enhanced person-to-person transmission in  
78 some geographic areas, and they have since been detected in several countries worldwide. For  
79 example, the UK B.1.1.7 variant spread rapidly in southeast England where it caused large  
80 numbers of COVID-19 cases,<sup>14</sup> and was identified shortly thereafter in the United States (US)  
81 [CDC; <https://www.cdc.gov/coronavirus/2019-ncov/transmission/variant.html>].<sup>23</sup> More than  
82 1,600 cases have since been documented in the US, and at least one large outbreak recently  
83 was reported in a Michigan prison.<sup>24, 25</sup> There is concern at the Centers for Disease Control and  
84 Prevention (CDC) that it could become the dominant variant causing disease in the US by  
85 March.<sup>23, 24, 26</sup> Moreover, the UK B.1.1.7 variant may be linked to an increased death rate  
86 compared to other virus types, adding further concern.<sup>18, 21, 27, 28</sup>

87 Similarly, the South Africa and Brazil variants caused large disease outbreaks in their  
88 respective countries.<sup>19, 20</sup> These variants also are of concern because they contain a mutation  
89 (E484K) in the spike protein that decreases efficacy of some therapeutic mAbs, decreases *in*  
90 *vitro* virus neutralization, and may result in potential escape from immunity induced by natural  
91 infection or vaccination.<sup>29-37</sup> All three variants (UK B.1.1.7, Brazil P.1, and South Africa B.1.351)  
92 also have a N501Y mutation in spike protein that is associated with stronger binding to the  
93 ACE2 receptor, possibly contributing to increased transmissibility.<sup>38,39</sup>

94 The Houston metropolitan area is the fourth largest and most ethnically diverse city in  
95 the US, with a population of approximately 7 million ([https://www.houston.org/houston-](https://www.houston.org/houston-data)  
96 [data](https://www.houston.org/houston-data)).<sup>40</sup> The 2,400-bed Houston Methodist health system has eight hospitals and cares for a  
97 large, multiethnic, and geographically and socioeconomically diverse patient population  
98 throughout greater Houston. The eight Houston Methodist hospitals have a single central  
99 molecular diagnostic laboratory, which means that all RT-PCR-specimens can readily be  
100 identified, banked, and subjected to further study as needed. In addition, the Department of  
101 Pathology and Genomic Medicine has a long-standing record of integrating genome sequencing  
102 efforts into clinical care and research, especially related to microbial pathogens infecting our  
103 patients.<sup>41-49</sup> In the aggregate, strategic co-localization of these diagnostic attributes coupled  
104 with a contiguous research institute building seamlessly facilitates comprehensive population  
105 genomic studies of SARS-CoV-2 viruses causing infections in the Houston metropolitan region.  
106 <sup>46, 49</sup>

107 Before the SARS-CoV-2 virus arrived in Houston, we planned an integrated strategy to  
108 confront and mitigate this microbial threat to our patients. In addition to rapidly validating an

109 RT-PCR test for the virus, we instituted a plan to sequence the genome of every positive  
110 specimen from patients within the Houston Methodist system, with the goal of understanding  
111 pathogen spread in our community and identifying biologically-important mutant viruses. We  
112 previously described the detailed population genomics of the first and second waves of SARS-  
113 CoV-2 in the Houston metropolitan region.<sup>46,49</sup> We have continued to sequence positive SARS-  
114 CoV-2 specimens with the goal of monitoring for variants of concern and genome mutations  
115 that may be associated with patient outcome or therapeutic failure.

116 This report describes the identification of multiple isolates of important SARS-CoV-2  
117 variants, including the UK B.1.1.7, South Africa B.1.351, Brazil P.1 and P.2, and California  
118 B.1.429 and B.1.427 variants in Houston patient specimens collected from December 2020  
119 through mid-February 2021. These findings represent the first detection of the South Africa and  
120 Brazil variants in Texas and only the second time UK variants have been identified in Houston.  
121 Greater Houston is the first metroplex in the US documented to have all of these important and  
122 concerning variants circulating among its residents. Our discoveries further illustrate the need  
123 for increased population genomic and epidemiology efforts to identify and help track  
124 dissemination of these variants, monitor development of new variants, and assess the  
125 relationship between variants and COVID-19 disease outcomes.

126

127

128

## 129 **Materials and Methods**

## 130 Patient Specimens

131 All specimens were obtained from individuals who were registered patients at Houston  
132 Methodist hospitals, associated facilities (e.g. urgent care centers), or institutions in the greater  
133 Houston metropolitan region that use our laboratory services. Virtually all individuals had signs  
134 or symptoms consistent with COVID-19 disease. This work was approved by the Houston  
135 Methodist Research Institute Institutional Review Board (IRB1010-0199).

136

## 137 SARS-CoV-2 Molecular Diagnostic Testing

138 Specimens obtained from symptomatic patients with a high degree of suspicion for COVID-19  
139 disease were tested in the Molecular Diagnostics Laboratory at Houston Methodist Hospital  
140 using assays granted Emergency Use Authorization (EUA) from the FDA  
141 ([https://www.fda.gov/medical-devices/emergency-situations-medical-devices/faqs-diagnostic-](https://www.fda.gov/medical-devices/emergency-situations-medical-devices/faqs-diagnostic-testing-sars-cov-2#offeringtests)  
142 [testing-sars-cov-2#offeringtests](https://www.fda.gov/medical-devices/emergency-situations-medical-devices/faqs-diagnostic-testing-sars-cov-2#offeringtests)). Multiple molecular testing platforms were used, including the  
143 COVID-19 test or RP2.1 test with BioFire Film Array instruments, the Xpert Xpress SARS-CoV-2  
144 test using Cepheid GeneXpert Infinity or Cepheid GeneXpert Xpress IV instruments, the SARS-  
145 CoV-2 Assay using the Hologic Panther instrument, the Aptima SARS-CoV-2 Assay using the  
146 Hologic Panther Fusion system and the SARS-CoV-2 assay using Abbott Alinity m instruments.  
147 All assays were performed according to the manufacturer's instructions. Testing was performed  
148 on material obtained from nasopharyngeal, oropharyngeal, or nasal swabs immersed in  
149 universal transport media (UTM), bronchoalveolar lavage fluid, or sputum treated with  
150 dithiothreitol (DTT). To standardize specimen collection, an instructional video was created for  
151 Houston Methodist healthcare workers (<https://vimeo.com/396996468/2228335d56>).

152

## 153 SARS-CoV-2 Genome Sequencing

154 Libraries for whole virus genome sequencing were prepared according to version 3 of the ARTIC  
155 nCoV-2019 sequencing protocol (<https://artic.network/ncov-2019>). Long reads were generated  
156 with the LSK-109 sequencing kit, 24 native barcodes (NBD104 and NBD114 kits), and a GridION  
157 instrument (Oxford Nanopore). Short sequence reads were generated with either a NextSeq  
158 550 or NovaSeq 6000 instrument (Illumina).

159

## 160 SARS-CoV-2 Genome Sequence Analysis

161 Viral genomes were assembled with the BV-BRC SARS-Cov2 assembly service ([https://www.bv-](https://www.bv-brc.org/app/ComprehensiveSARS2Analysis)  
162 [brc.org/app/ComprehensiveSARS2Analysis](https://www.bv-brc.org/app/ComprehensiveSARS2Analysis)).<sup>50</sup> The One Codex SARS-CoV-2 variant calling and  
163 consensus assembly pipeline was chosen for assembling all sequences  
164 (<https://github.com/onecodex/sars-cov-2.git>) using default parameters and a minimum read  
165 depth of 3. Briefly, the pipeline uses seqtk version 1.3-r116 for sequence trimming  
166 (<https://github.com/lh3/seqtk.git>); minimap version 2.1<sup>51</sup> for aligning reads against reference  
167 genome Wuhan-Hu-1 (NC\_045512.2); samtools version 1.11 for sequence and file  
168 manipulation<sup>52</sup>; and iVar version 1.2.2 for primer trimming and variant calling.<sup>53</sup>

169

## 170 Geospatial Analysis

171 The patient home address zip codes were used to visualize the geospatial distribution of spread  
172 for each variant of concern. Figures were generated using Tableau version 2020.3.4.

173



174

## 175 **Results**

176 Since the start of the SARS-CoV-2 pandemic, we have sequenced 20,453 specimens collected  
177 from patients in the Houston metropolitan area. In genome sequencing conducted in January  
178 and February 2021, we discovered our first variants of concern. These included 23 UK variants  
179 (B.1.1.7), two South African variants (B.1.351), and four Brazilian variants (P.1). We also  
180 identified 162 patients infected with the California variants (B.1.429,  $N = 143$ ; B.1.427,  $N = 19$ )  
181 and 39 patients infected with Brazil P.2 variants 2020 (Table 1).

182

### 183 UK Variant of Concern (B.1.1.7)

184 The UK variant known as B.1.1.7 was first identified in September 2020 in the UK and was  
185 designated as a variant of concern in South London on December 14, 2020. It was strongly  
186 associated with a resurgence of SARS-CoV-2 infections in that region and rapidly became the  
187 dominant lineage.<sup>26</sup> Importantly, the UK has the most extensive SARS-CoV-2 genome  
188 sequencing program in the world, making them particularly well situated to rapidly identify new  
189 variants. Of the ~500,000 SARS-CoV-2 genome sequences submitted to GISAID from global  
190 sources, approximately one-half originated from collaborating laboratories in the UK as part of  
191 the COVID-19 Genomics UK Consortium.<sup>54, 55</sup>

192 The UK B.1.1.7 variant is of particular concern because it has an unusually large number  
193 of genome mutations, including multiple changes in spike protein (Figure 1). Some of the  
194 mutations of primary concern include N501Y located in the receptor binding domain, and a two  
195 amino acid deletion (del69-70) that has arisen in multiple SARS-CoV-2 genetic backgrounds and

196 is associated with increased transmissibility<sup>26</sup>. In addition, evidence has been presented from  
197 the UK that B.1.1.7 strains may cause increased hospitalization and mortality.<sup>18, 21, 27, 56</sup> The first  
198 patient we identified in Houston with a B.1.1.7 variant was diagnosed the second week of  
199 January, 2020; thus far we have identified 23 patients with this variant of concern (Table 1). Of  
200 note, none of our first three patients had an international travel history, suggesting that they  
201 acquired the B.1.1.7 infections either locally or during domestic travel. Preliminary evidence  
202 indicates that immune sera from the Pfizer-BioNTech SARS-CoV-2 vaccine retain the ability to  
203 neutralize B.1.1.7 variants *in vitro*.<sup>57</sup> Additional studies have found that convalescent plasma  
204 from many patients, and some monoclonal antibody therapies, retain the ability to neutralize  
205 B.1.1.7 variant SARS-CoV-2 *in vitro*.<sup>34, 35</sup>

206

## 207 South Africa Variant of Concern (B.1.351)

208 The South Africa B.1.351 variant of concern was first identified in a COVID-19 epidemic wave  
209 occurring in Nelson Mandela Bay in October 2020.<sup>19</sup> This variant was concerning because of its  
210 large number of spike protein mutations (including K417N, E484K, and N501Y) (Figure 1) and  
211 apparent increased transmissibility.<sup>19, 38</sup> These three mutations are located in the receptor  
212 binding domain of spike and may decrease the effectiveness of some mAb therapies and  
213 vaccines.<sup>29-31, 34, 35, 58</sup> The first South Africa variant detected in Houston was identified in a  
214 patient specimen we collected the last week of December, 2020, and the second patient's  
215 specimen was collected the first week of January, 2021. Of note, these Houston Methodist  
216 Hospital patients had no known international travel history, suggesting domestic acquisition of  
217 this B.1.351 variant.

218

## 219 Brazil Variants of Concern (P.1 and P.2)

220 The P.1 variant of concern was reported to have originated in Manaus, Brazil, and like the South  
221 Africa B.1.351 variant, has numerous mutations in spike protein, including E484K and N501Y  
222 (Figure 1).<sup>59</sup> We identified our first P.1 variant in Houston specimens the third week of January,  
223 2021. In total, we have identified four P.1 variants in our patient samples (Table 1). The P.2  
224 variant began to spread in Brazil in earnest in October of 2020, similar to P.1.<sup>60, 61</sup> It also has a  
225 E484K amino acid change in the RBD of spike protein (Figure 1), similar to variant P.1 and  
226 B.1.351.<sup>17</sup> We first identified a P.2 variant in a patient specimen obtained the last week of  
227 December, 2020. In total, we have documented 39 P.2 variants in our patient specimens (Table  
228 1).

229

## 230 California Variants (B.1.429 and B.1.427)

231 The emergence of what became known as the California variant, originally known as CAL.20C  
232 and later designated as lineages B.1.429 and B.1.427, was first identified in Los Angeles County  
233 in July 2020 as a single isolate.<sup>62, 63</sup> This variant re-emerged in October 2020 and was associated  
234 with an increasing number of cases during a wave of SARS-CoV-2 infections in the region.<sup>16</sup>  
235 Variant B.1.429 accounted for 36% of isolates collected from late November to late December  
236 2020 in Los Angeles County.<sup>16</sup> Since November 2020, this variant has been detected in 42 states  
237 in the US,<sup>63</sup> and was first found in Houston Methodist Hospital patients in specimens obtained  
238 the last week of December, 2020. We identified 143 and 19 patients with the B.1.429 and  
239 B.1.427 isolates, respectively (Table 1). The B.1.427 variant is closely related to B.1.429 (Figure

240 1) and has spread from California to 34 states since October 2020.<sup>62</sup> The California variants are  
241 noteworthy primarily for their emergence and very rapid spread in Los Angeles County and  
242 identification elsewhere in the US. However, as of February 17, 2021, they have not been  
243 designated as variants of concern by the Centers for Disease Control.

244

## 245 Geospatial Distribution of Variants

246 Given the importance of the identification of these SARS-CoV-2 variants in the Houston  
247 metropolitan area, we examined their geospatial distribution to investigate the extent of  
248 dissemination (Figure 2). With the exception of the B.1.351 variant, patients infected with all  
249 other variants resided in widely dispersed areas of the metropolitan area. This finding is  
250 consistent with the well-known propensity of SARS-CoV-2 to spread rapidly between  
251 individuals, and especially so for these variants of concern<sup>19, 23, 24, 27, 64-66</sup>.

252

## 253 Discussion

254 Here we report discovery of the UK (B.1.1.7), South Africa (B.1.351), and Brazil (P.1)  
255 SARS-CoV-2 variants of concern from patients in the Houston metropolitan region. We also  
256 identified geographically-widespread dissemination of the Cal.20C California (B.1.429 and  
257 B.1.427) variants of interest. These four SARS-CoV-2 variants are distributed across a large  
258 geospatial region in the metropolitan region (Figure 2), indicating successful patient-to-patient  
259 transmission among Houstonians. None of the affected patients were from a common  
260 household or reported recent international travel, suggesting that every infection was  
261 independently acquired locally or during domestic travel. Given that Houston is a culturally- and

262 ethnically-diverse population center with two international airports, a major shipping center,  
263 and a global energy sector, the discovery of patients infected with each of the four concerning  
264 SARS-CoV-2 variants is not unexpected but it is disquieting. With this report, Houston now  
265 becomes the first US city to document patients infected with each of the four SARS-CoV-2  
266 variants of concern or interest, testament to our aggressive sequencing of COVID-19 patient  
267 samples.

268         The P.2 variant gained recent attention in the scientific and lay press because it has  
269 been reported to cause SARS-CoV-2 reinfections.<sup>67, 68</sup> We identified 39 P.2 infections among  
270 Houston patients. Although it is currently a numerically minor cause of all Houston-area  
271 infections, P.2 is now the most common SARS-CoV-2 variant of concern in our population.

272         The E484K amino acid replacement in spike protein is characteristic of P.1, P.2, and  
273 B.1.351 strains (Figure 1). It has independently arisen in many different SARS-CoV-2 genomic  
274 backgrounds, including some B.1.1.7 strains.<sup>69</sup> This amino acid replacement has caused  
275 substantial public health concern due to its potentially detrimental effects on neutralizing  
276 activity of therapeutic mAbs, sera obtained from naturally infected individuals, and post-  
277 vaccination sera.<sup>70, 71</sup> That is, the E484K amino acid change may facilitate vaccine escape.  
278 Among our Houston SARS-CoV-2 genomes, E484K was detected 84 times (0.4% of the total  
279 genomes sequenced). It was first detected in a respiratory specimen collected in July 2020, near  
280 the peak of our second massive wave of infections,<sup>46</sup> and has been identified in many diverse  
281 genomic backgrounds thereafter. Due to this strong signal of convergent evolution, we will  
282 continue to closely monitor all Houston SARS-CoV-2 genomes for the E484K amino acid change.

283           Recently, the Q677H amino acid change in spike protein has been identified in SARS-  
284 CoV-2 patient samples collected in multiple US states and other global locations.<sup>72,73</sup> Q677H has  
285 arisen in at least six distinct genomic backgrounds.<sup>73</sup> A Q667P amino acid change has also been  
286 identified.<sup>73</sup> Among the Houston genomes, Q677H occurred 288 times (1.4%) and is encoded  
287 by two different nucleotide changes. We also identified two other amino acid changes, 677P (in  
288 330 genomes, 1.6%) and Q677K (2 genomes, <0.1%) in Houston. Taken together, these data  
289 suggest selection for a yet to be determined biologic phenotype associated with amino acid  
290 replacements at position 677.

291           Many population genomic studies performed in various global locations have clearly  
292 demonstrated that SARS-CoV-2 variants with biologically-relevant phenotypes have evolved.  
293 Emergence of new variants underscores the need for ongoing extensive genomic sequencing  
294 efforts for early identification and public health warning. In support of these efforts, our  
295 laboratory has devoted substantial resources to SARS-CoV-2 genomics, resulting in sequence  
296 analysis of more genomes than any other state in the US.<sup>54</sup> Since March 2020, approximately  
297 36,500 SARS-CoV-2 positive patients have received care in our Houston Methodist health  
298 system, and we have sequenced 20,453 virus genomes. In total, this dataset represents 56% of  
299 our Houston Methodist COVID-19 patients. Inasmuch as almost 500,000 COVID-19 infections  
300 have been reported in the Houston metropolitan area,<sup>74</sup> we have sequenced the genome of  
301 4.1% of all cases reported in our area. Based on modeling, this sample depth may be sufficient  
302 to identify all variants occurring at a biologically-relevant frequency.<sup>75</sup> Due to the very wide  
303 geographic catchment of our eight-hospital system that serves a very diverse patient  
304 population, the data presented here likely reflect a reasonably detailed overview of SARS-CoV-2

305 genomic diversity throughout our metroplex. This comparatively deep sampling of the Houston  
306 metropolitan SARS-CoV-2 population enabled us to identify patients infected with variants of  
307 concern, and provided information regarding the timeframe of initial presence and frequency  
308 of each variant. We modeled our strategy on the aggressive genome sequencing being  
309 conducted in the UK, a global leader in SARS-CoV-2 genome sequencing.<sup>76</sup>

310 Our large SARS-CoV-2 genome dataset and comprehensive infrastructure are unique  
311 resources. By linking the SARS-CoV-2 whole genome sequence data to patient metadata  
312 present in our electronic medical record, we are able to use analytic tools such as high-  
313 performance compute clusters and machine learning to investigate the relationship between  
314 genomic diversity and phenotypic traits such as strain virulence or patient outcomes.<sup>46</sup> For  
315 example, recent reports of increased mortality caused by B.1.1.7 variant strains are very  
316 concerning and worthy of further investigation.<sup>18, 21, 27, 28</sup> Similarly, our COVID-19 biobank has  
317 cryopreserved respiratory samples, white blood cells, serum, plasma, and formalin-fixed  
318 paraffin-embedded tissues for use in downstream investigations such as viral neutralization  
319 assays, RNA sequencing, and immune repertoire analysis.

320 Our goal is to sequence the SARS-CoV-2 genome of every infected patient in our health  
321 care system in near-real time, and expand outward to other patients in our community.  
322 Consistent with these goals, the American Rescue Plan announced by the Biden administration  
323 proposes to substantially fund sequencing capacity in the US. However, it remains unclear how  
324 these important funds will be distributed.<sup>77</sup> Our results from a major metropolitan region in the  
325 US underscore the necessity of greatly increased genome surveillance to rapidly identify and  
326 track the emergence and introduction of SARS-CoV-2 variants in the US and local areas.

327

328

329

330

331

## 332 **Acknowledgments**

333 We thank Drs. Jessica Thomas and Zejuan Li, Erika Walker, the many very talented and  
334 dedicated molecular technologists, and many labor pool volunteers in the Molecular  
335 Diagnostics Laboratory and Methodist Research Institute for their dedicated efforts. We are  
336 indebted to Drs. Marc Boom and Dirk Sostman for their support, to many very generous  
337 Houston philanthropists for their tremendous support and to the Houston Methodist Academic  
338 Institute Infectious Diseases Fund that have made this ongoing project possible. James Davis  
339 and Robert Olson were funded in whole or in part with Federal funds from the National  
340 Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health  
341 and Human Services, under Contract No. 75N93019C00076. We thank Jessica W. Podnar and  
342 personnel in the University of Texas Genome Sequencing and Analysis Facility for sequencing  
343 some of the genomes in this study. We acknowledge the assistance of Maulik Shukla and  
344 Marcus Nguyen at PATRIC Bioinformatics Resource Center for their assistance with sequence  
345 analysis. We gratefully acknowledge the originating and submitting laboratories of the SARS-  
346 CoV-2 genome sequences from GISAID's EpiFlu™ Database used in some of the work presented  
347 here. We also thank many colleagues for critical reading of the manuscript and suggesting



348 improvements, and Dr. Kathryn Stockbauer, Sasha Pejerrey, Adrienne Winston, and Heather  
349 McConnell for help with figures, tables, and editorial contributions.

350

## 351 **Author Contributions**

352 J.M.M. conceptualized and designed the project; S.W.L, R.J.O., P.A.C., S.S., R.O., J.J.D., M.S., P.Y.,  
353 L.P., K.R., M.N.S, J.C., I.J.F, and J.G. performed research. All authors contributed to writing the  
354 manuscript.

355

356

357 Data availability: All genomes have been submitted to GISAID ([www.gisaid.org](http://www.gisaid.org))

358

359

360

## 361 **References**

- 362 [1] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J,  
363 Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q,  
364 Wang J, Cao B: Clinical features of patients infected with 2019 novel coronavirus in Wuhan,  
365 China. *Lancet* 2020, 395:497-506.
- 366 [2] Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F,  
367 Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W: A Novel Coronavirus from Patients with  
368 Pneumonia in China, 2019. *New England Journal of Medicine* 2020, 382:727-33.
- 369 [3] Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, Xing F, Liu J, Yip CC, Poon RW, Tsoi HW, Lo SK,  
370 Chan KH, Poon VK, Chan WM, Ip JD, Cai JP, Cheng VC, Chen H, Hui CK, Yuen KY: A familial cluster  
371 of pneumonia associated with the 2019 novel coronavirus indicating person-to-person  
372 transmission: a study of a family cluster. *Lancet* 2020, 395:514-23.
- 373 [4] Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, Hu Y, Tao ZW, Tian JH, Pei YY, Yuan ML,  
374 Zhang YL, Dai FH, Liu Y, Wang QM, Zheng JJ, Xu L, Holmes EC, Zhang YZ: A new coronavirus  
375 associated with human respiratory disease in China. *Nature* 2020, 579:265-9.
- 376 [5] World Health Organization Coronavirus Disease 2019 (COVID-19) Situation Report. 2020.
- 377 [6] Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA, Haagmans BL,  
378 Lauber C, Leontovich AM, Neuman BW, Penzar D, Perlman S, Poon LLM, Samborskiy DV, Sidorov  
379 IA, Sola I, Ziebuhr J, Coronaviridae Study Group of the International Committee on Taxonomy of  
380 V: The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV  
381 and naming it SARS-CoV-2. *Nature Microbiology* 2020, 5:536-44.

- 382 [7] Wang C, Horby PW, Hayden FG, Gao GF: A novel coronavirus outbreak of global health  
383 concern. *Lancet* 2020, 395:470-3.
- 384 [8] Perlman S: Another Decade, Another Coronavirus. *New England Journal of Medicine* 2020,  
385 382:760-2.
- 386 [9] Allel K, Tapia-Muñoz T, Morris W: Country-level factors associated with the early spread of  
387 COVID-19 cases at 5, 10 and 15 days since the onset. *Glob Public Health* 2020:1-14.
- 388 [10] Chen P, Nirula A, Heller B, Gottlieb RL, Boscia J, Morris J, Huhn G, Cardona J, Mocherla B,  
389 Stosor V, Shawa I, Adams AC, Van Naarden J, Custer KL, Shen L, Durante M, Oakley G, Schade  
390 AE, Sabo J, Patel DR, Klekotka P, Skovronsky DM, Investigators B-: SARS-CoV-2 Neutralizing  
391 Antibody LY-CoV555 in Outpatients with Covid-19. *N Engl J Med* 2021, 384:229-37.
- 392 [11] Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, Musser BJ, Soo Y, Rofail  
393 D, Im J, Perry C, Pan C, Hosain R, Mahmood A, Davis JD, Turner KC, Hooper AT, Hamilton JD,  
394 Baum A, Kyratsous CA, Kim Y, Cook A, Kampman W, Kohli A, Sachdeva Y, Graber X, Kowal B,  
395 DiCioccio T, Stahl N, Lipsich L, Braunstein N, Herman G, Yancopoulos GD, Trial I: REGN-COV2, a  
396 Neutralizing Antibody Cocktail, in Outpatients with Covid-19. *N Engl J Med* 2021, 384:238-51.
- 397 [12] Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA,  
398 Roupael N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H,  
399 Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L,  
400 Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S,  
401 Ivarsson M, Miller J, Zaks T, Group CS: Efficacy and Safety of the mRNA-1273 SARS-CoV-2  
402 Vaccine. *N Engl J Med* 2021, 384:403-16.

- 403 [13] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Perez Marc G,  
404 Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper  
405 D, Frenck RW, Jr., Hammitt LL, Tureci O, Nell H, Schaefer A, Unal S, Tresnan DB, Mather S,  
406 Dormitzer PR, Sahin U, Jansen KU, Gruber WC, Group CCT: Safety and Efficacy of the BNT162b2  
407 mRNA Covid-19 Vaccine. *N Engl J Med* 2020, 383:2603-15.
- 408 [14] Rambaut A, Loman N, Pybus O, Barclay W, Barrett J, Carabelli A, Connor T, Peacock T,  
409 Robertson DL, Volzon E, (CoG-UK) C-GCU: Preliminary genomic characterisation of an emergent  
410 SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations. 2020.
- 411 [15] Naveca F, Nascimento V, Souza V, Corado A, Nascimento F, Silva G, Costa Á, Duarte D,  
412 Pessoa K, Gonçalves L, Brandão MJ, Jesus M, Fernandes C, Pinto R, Silva M, Mattos T, Wallau  
413 GL, Siqueira MM, Resende PC, Delatorre E, Gräf T, Bello G: Phylogenetic relationship of SARS-  
414 CoV-2 sequences from Amazonas with emerging Brazilian variants harboring mutations E484K  
415 and N501Y in the Spike protein. 2021.
- 416 [16] Zhang W, Davis BD, Chen SS, Sincuir Martinez JM, Plummer JT, Vail E: Emergence of a Novel  
417 SARS-CoV-2 Variant in Southern California. *JAMA* 2021.
- 418 [17] Voloch CM, Silva F Rd, de Almeida LGP, Cardoso CC, Brustolini OJ, Gerber AL, Guimarães  
419 APdC, Mariani D, Costa RMd, Ferreira OC, Cavalcanti AC, Frauches TS, de Mello CMB, Galliez  
420 RM, Faffe DS, Castiñeiras TMPP, Tanuri A, de Vasconcelos ATR: Genomic characterization of a  
421 novel SARS-CoV-2 lineage from Rio de Janeiro, Brazil. *medRxiv* 2020:2020.12.23.20248598.
- 422 [18] Challen R, Brooks-Pollock E, Read JM, Dyson L, Tsaneva-Atanasova K, Danon L: Increased  
423 hazard of mortality in cases compatible with SARS-CoV-2 variant of concern 202012/1 - a  
424 matched cohort study. *medRxiv* 2021:2021.02.09.21250937.

425 [19] Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, Doolabh D, Pillay  
426 S, San EJ, Msomi N, Mlisana K, von Gottberg A, Walaza S, Allam M, Ismail A, Mohale T, Glass AJ,  
427 Engelbrecht S, Van Zyl G, Preiser W, Petruccione F, Sigal A, Hardie D, Marais G, Hsiao M,  
428 Korsman S, Davies M-A, Tyers L, Mudau I, York D, Maslo C, Goedhals D, Abrahams S, Laguda-  
429 Akingba O, Alisoltani-Dehkordi A, Godzik A, Wibmer CK, Sewell BT, Lourenço J, Alcantara LCJ,  
430 Pond SLK, Weaver S, Martin D, Lessells RJ, Bhiman JN, Williamson C, de Oliveira T: Emergence  
431 and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-  
432 2) lineage with multiple spike mutations in South Africa. medRxiv 2020:2020.12.21.20248640.  
433 [20] Bradshaw D, Laubscher R, Dorrington R, Groenewald P, Moultrie T: Report on Weekly  
434 Deaths in South Africa: 1 January-8 December 2020 (Week 49). Burden of Disease Research  
435 Unit, South African Medical Research Council 2020.  
436 [21] Iacobucci G: Covid-19: New UK variant may be linked to increased death rate, early data  
437 indicate. BMJ 2021, 372:n230.  
438 [22] Faria NR, Claro IM, Candido D, Franco LAM, Andrade PS, Coletti TM, Silva CAM, Sales FC,  
439 Manuli ER, Aguiar RS, Gaburo N, Camilo CdC, Fraiji NA, Crispim MAE, Carvalho MdPSS, Rambaut  
440 A, Loman N, Pybus OG, Sabino EC, Network CG: Genomic characterisation of an emergent SARS-  
441 CoV-2 lineage in Manaus: preliminary findings. virological.org, 2021.  
442 [23] Alpert T, Lasek-Nesselquist E, Brito AF, Valesano AL, Rothman J, MacKay MJ, Petrone ME,  
443 Breban MI, Watkins AE, Vogels CBF, Russell A, Kelly JP, Shudt M, Plitnick J, Schneider E,  
444 Fitzsimmons WJ, Khullar G, Metti J, Dudley JT, Nash M, Wang J, Liu C, Hui P, Muyombwe A,  
445 Downing R, Razeq J, Bart SM, Murphy S, Neal C, Laszlo E, Landry ML, Cook PW, Fauver JR,  
446 Mason CE, Luring AS, St George K, MacCannell DR, Grubaugh ND: Early introductions and

447 community transmission of SARS-CoV-2 variant B.1.1.7 in the United States. medRxiv  
448 2021:2021.02.10.21251540.

449 [24] Washington NL, Gangavarapu K, Zeller M, Bolze A, Cirulli ET, Schiabor Barrett KM, Larsen  
450 BB, Anderson C, White S, Cassens T, Jacobs S, Levan G, Nguyen J, Ramirez JM, Rivera-Garcia C,  
451 Sandoval E, Wang X, Wong D, Spencer E, Robles-Sikisaka R, Kurzban E, Hughes LD, Deng X,  
452 Wang C, Servellita V, Valentine H, De Hoff P, Seaver P, Sathe S, Gietzen K, Sickler B, Antico J,  
453 Hoon K, Liu J, Harding A, Bakhtar O, Basler T, Austin B, Isaksson M, Febbo P, Becker D, Laurent  
454 M, McDonald E, Yeo GW, Knight R, Laurent LC, de Feo E, Worobey M, Chiu C, Suchard MA, Lu  
455 JT, Lee W, Andersen KG: Genomic epidemiology identifies emergence and rapid transmission of  
456 SARS-CoV-2 B.1.1.7 in the United States. medRxiv 2021:2021.02.06.21251159.

457 [25] Jackson A: 90 cases of UK COVID-19 variant B.1.1.7 reported at Michigan prison, state says.  
458 Detroit Free Press. Detroit: Detroit Free Press, 2021.

459 [26] Galloway SE, Paul P, MacCannell DR, Johansson MA, Brooks JT, MacNeil A, Slayton RB, Tong  
460 S, Silk BJ, Armstrong GL, Biggerstaff M, Dugan VG: Emergence of SARS-CoV-2 B.1.1.7 Lineage -  
461 United States, December 29, 2020-January 12, 2021. MMWR Morb Mortal Wkly Rep 2021,  
462 70:95-9.

463 [27] B.1.1.7. NaERVTAGNoncC-v: NERVTAG paper on COVID-19 variant of concern B.1.1.7.  
464 Edited by Care DoHaS, Emergencies SAGf. United Kingdom: GOV.UK, 2021.

465 [28] Munitz A, Yechezkel M, Dickstein Y, Yamin D, Gerlic M: The rise of SARS-CoV-2 variant  
466 B.1.1.7 in Israel intensifies the role of surveillance and vaccination in elderly. medRxiv  
467 2021:2021.02.16.21251819.

- 468 [29] Wang WB, Liang Y, Jin YQ, Zhang J, Su JG, Li QM: E484K mutation in SARS-CoV-2 RBD  
469 enhances binding affinity with hACE2 but reduces interactions with neutralizing antibodies and  
470 nanobodies: Binding free energy calculation studies. bioRxiv 2021.
- 471 [30] Garcia-Beltran WF, Lam EC, Denis KS, Nitido AD, Garcia ZH, Hauser BM, Feldman J, Pavlovic  
472 MN, Gregory DJ, Poznansky MC, Sigal A, Schmidt AG, Iafrate AJ, Naranbhai V, Balazs AB:  
473 Circulating SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity.  
474 medRxiv 2021.
- 475 [31] Liu H, Wei P, Zhang Q, Chen Z, Aviszus K, Downing W, Peterson S, Reynoso L, Downey GP,  
476 Frankel SK, Kappler J, Marrack P, Zhang G: 501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose  
477 binding to Bamlanivimab in vitro. bioRxiv 2021.
- 478 [32] Yuan M, Huang D, Lee C-CD, Wu NC, Jackson AM, Zhu X, Liu H, Peng L, van Gils MJ, Sanders  
479 RW, Burton DR, Reincke SM, Prüss H, Kreye J, Nemazee D, Ward AB, Wilson IA: Structural and  
480 functional ramifications of antigenic drift in recent SARS-CoV-2 variants. bioRxiv 2021.
- 481 [33] Greaney AJ, Loes AN, Crawford KHD, Starr TN, Malone KD, Chu HY, Bloom JD:  
482 Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect  
483 recognition by polyclonal human plasma antibodies. Cell host & microbe 2021.
- 484 [34] Tada T, Dcosta BM, Samanovic-Golden M, Herati RS, Cornelius A, Mulligan MJ, Landau NR:  
485 Neutralization of viruses with European, South African, and United States SARS-CoV-2 variant  
486 spike proteins by convalescent sera and BNT162b2 mRNA vaccine-elicited antibodies. bioRxiv  
487 2021.
- 488 [35] Planas D, Bruel T, Grzelak L, Guivel-Benhassine F, Staropoli I, Porrot F, Planchais C,  
489 Buchrieser J, Rajah MM, Bishop E, Albert M, Donati F, Behillil S, Enouf V, Maquart M, Gonzalez

490 M, De Sèze J, Péré H, Veyer D, Sève A, Simon-Lorière E, Fafi-Kremer S, Stefic K, Mouquet H,  
491 Hocqueloux L, van der Werf S, Prazuck T, Schwartz O: Sensitivity of infectious SARS-CoV-2  
492 B.1.1.7 and B.1.351 variants to neutralizing antibodies. bioRxiv 2021.

493 [36] Wang P, Liu L, Iketani S, Luo Y, Guo Y, Wang M, Yu J, Zhang B, Kwong PD, Graham BS,  
494 Mascola JR, Chang JY, Yin MT, Sobieszczyk M, Kyratsous CA, Shapiro L, Sheng Z, Nair MS, Huang  
495 Y, Ho DD: Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody  
496 Neutralization. bioRxiv 2021.

497 [37] Cele S, Gazy I, Jackson L, Hwa S-H, Tegally H, Lustig G, Giandhari J, Pillay S, Wilkinson E,  
498 Naidoo Y, Karim F, Ganga Y, Khan K, Balazs AB, Gosnell BI, Hanekom W, Moosa M-YS, Lessells  
499 RJ, de Oliveira T, Sigal A: Escape of SARS-CoV-2 501Y.V2 variants from neutralization by  
500 convalescent plasma. medRxiv 2021.

501 [38] Nelson G, Buzko O, Spilman P, Niazi K, Rabizadeh S, Soon-Shiong P: Molecular dynamic  
502 simulation reveals E484K mutation enhances spike RBD-ACE2 affinity and the combination of  
503 E484K, K417N and N501Y mutations (501Y.V2 variant) induces conformational change greater  
504 than N501Y mutant alone, potentially resulting in an escape mutant. bioRxiv 2021.

505 [39] Tian F, Tong B, Sun L, Shi S, Zheng B, Wang Z, Dong X, Zheng P: Mutation N501Y in RBD of  
506 Spike Protein Strengthens the Interaction between COVID-19 and its Receptor ACE2. bioRxiv  
507 2021.

508 [40] Cline M, Emerson M, bratter j, howell j, Jeanty P: Houston Region Grows More  
509 Racially/Ethnically Diverse, With Small Declines in Segregation. A Joint Report Analyzing Census  
510 Data from 1990, 2000, and 2010, 2012.



511 [41] Wright AM, Beres SB, Consamus EN, Long SW, Flores AR, Barrios R, Richter GS, Oh SY,  
512 Garufi G, Maier H, Drews AL, Stockbauer KE, Cernoch P, Schneewind O, Olsen RJ, Musser JM:  
513 Rapidly progressive, fatal, inhalation anthrax-like infection in a human: case report, pathogen  
514 genome sequencing, pathology, and coordinated response. Arch Pathol Lab Med 2011,  
515 135:1447-59.

516 [42] Long SW, Beres SB, Olsen RJ, Musser JM: Absence of patient-to-patient intrahospital  
517 transmission of *Staphylococcus aureus* as determined by whole-genome sequencing. MBio  
518 2014, 5:e01692-14.

519 [43] Long SW, Olsen RJ, Eagar TN, Beres SB, Zhao P, Davis JJ, Brettin T, Xia F, Musser JM:  
520 Population Genomic Analysis of 1,777 Extended-Spectrum Beta-Lactamase-Producing *Klebsiella*  
521 *pneumoniae* Isolates, Houston, Texas: Unexpected Abundance of Clonal Group 307. MBio 2017,  
522 8.

523 [44] Nasser W, Beres SB, Olsen RJ, Dean MA, Rice KA, Long SW, Kristinsson KG, Gottfredsson M,  
524 Vuopio J, Raisanen K, Caugant DA, Steinbakk M, Low DE, McGeer A, Darenberg J, Henriques-  
525 Normark B, Van Beneden CA, Hoffmann S, Musser JM: Evolutionary pathway to increased  
526 virulence and epidemic group A *Streptococcus* disease derived from 3,615 genome sequences.  
527 Proc Natl Acad Sci U S A 2014, 111:E1768-76.

528 [45] Kachroo P, Eraso JM, Beres SB, Olsen RJ, Zhu L, Nasser W, Bernard PE, Cantu CC, Saavedra  
529 MO, Arredondo MJ, Strobe B, Do H, Kumaraswami M, Vuopio J, Grondahl-Yli-Hannuksela K,  
530 Kristinsson KG, Gottfredsson M, Pesonen M, Pensar J, Davenport ER, Clark AG, Corander J,  
531 Caugant DA, Gaini S, Magnussen MD, Kubiak SL, Nguyen HAT, Long SW, Porter AR, DeLeo FR,

532 Musser JM: Integrated analysis of population genomics, transcriptomics and virulence provides  
533 novel insights into *Streptococcus pyogenes* pathogenesis. Nat Genet 2019, 51:548-59.

534 [46] Long SW, Olsen RJ, Christensen PA, Bernard DW, Davis JJ, Shukla M, Nguyen M, Saavedra  
535 MO, Yerramilli P, Pruitt L, Subedi S, Kuo HC, Hendrickson H, Eskandari G, Nguyen HAT, Long JH,  
536 Kumaraswami M, Goike J, Boutz D, Gollihar J, McLellan JS, Chou CW, Javanmardi K, Finkelstein  
537 IJ, Musser JM: Molecular Architecture of Early Dissemination and Massive Second Wave of the  
538 SARS-CoV-2 Virus in a Major Metropolitan Area. mBio 2020, 11.

539 [47] Salazar E, Kuchipudi SV, Christensen PA, Eagar T, Yi X, Zhao P, Jin Z, Long SW, Olsen RJ,  
540 Chen J, Castillo B, Leveque C, Towers D, Lavinder J, Gollihar J, Cardona J, Ippolito G, Nissly R,  
541 Bird I, Greenawalt D, Rossi RM, Gontu A, Srinivasan S, Poojary I, Cattadori IM, Hudson PJ,  
542 Josleyn NM, Prugar L, Huie K, Herbert A, Bernard DW, Dye JM, Kapur V, Musser JM:  
543 Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and receptor-binding domain  
544 IgG correlate with virus neutralization. J Clin Invest 2020, 130:6728-38.

545 [48] Salazar E, Perez KK, Ashraf M, Chen J, Castillo B, Christensen PA, Eubank T, Bernard DW,  
546 Eagar TN, Long SW, Subedi S, Olsen RJ, Leveque C, Schwartz MR, Dey M, Chavez-East C, Rogers  
547 J, Shehabeldin A, Joseph D, Williams G, Thomas K, Masud F, Talley C, Dlouhy KG, Lopez BV,  
548 Hampton C, Lavinder J, Gollihar JD, Maranhao AC, Ippolito GC, Saavedra MO, Cantu CC,  
549 Yerramilli P, Pruitt L, Musser JM: Treatment of Coronavirus Disease 2019 (COVID-19) Patients  
550 with Convalescent Plasma. Am J Pathol 2020, 190:1680-90.

551 [49] Long SW, Olsen RJ, Christensen PA, Bernard DW, Davis JR, Shukla M, Nguyen M, Ojeda  
552 Saavedra M, Cantu CC, Yerramilli P, Pruitt L, Subedi S, Hendrickson H, Eskandari G,  
553 Kumaraswami M, McLellan JS, Musser JM: Molecular Architecture of Early Dissemination and

554 Evolution of the SARS-CoV-2 Virus in Metropolitan Houston, Texas. bioRxiv  
555 2020:2020.05.01.072652.

556 [50] Davis JJ, Wattam AR, Aziz RK, Brettin T, Butler R, Butler RM, Chlenski P, Conrad N,  
557 Dickerman A, Dietrich EM, Gabbard JL, Gerdes S, Guard A, Kenyon RW, Machi D, Mao C,  
558 Murphy-Olson D, Nguyen M, Nordberg EK, Olsen GJ, Olson RD, Overbeek JC, Overbeek R,  
559 Parrello B, Pusch GD, Shukla M, Thomas C, VanOeffelen M, Vonstein V, Warren AS, Xia F, Xie D,  
560 Yoo H, Stevens R: The PATRIC Bioinformatics Resource Center: expanding data and analysis  
561 capabilities. *Nucleic Acids Res* 2020, 48:D606-D12.

562 [51] Li H: Minimap2: pairwise alignment for nucleotide sequences. *Bioinformatics* 2018,  
563 34:3094-100.

564 [52] Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R,  
565 Genome Project Data Processing S: The Sequence Alignment/Map format and SAMtools.  
566 *Bioinformatics* 2009, 25:2078-9.

567 [53] Grubaugh ND, Gangavarapu K, Quick J, Matteson NL, De Jesus JG, Main BJ, Tan AL, Paul LM,  
568 Brackney DE, Grewal S, Gurfield N, Van Rompay KKA, Isern S, Michael SF, Coffey LL, Loman NJ,  
569 Andersen KG: An amplicon-based sequencing framework for accurately measuring intrahost  
570 virus diversity using PrimalSeq and iVar. *Genome Biol* 2019, 20:8.

571 [54] Shu Y, McCauley J: GISAID: Global initiative on sharing all influenza data - from vision to  
572 reality. *Euro Surveill* 2017, 22.

573 [55] COVID-19 Genomics UK Consortium. 2021.

- 574 [56] Davies NG, Jarvis CI, Edmunds WJ, Jewell NP, Diaz-Ordaz K, Keogh RH: Increased hazard of  
575 death in community-tested cases of SARS-CoV-2 Variant of Concern 202012/01. medRxiv  
576 2021:2021.02.01.21250959.
- 577 [57] Muik A, Wallisch AK, Sanger B, Swanson KA, Muhl J, Chen W, Cai H, Maurus D, Sarkar R,  
578 Tureci O, Dormitzer PR, Sahin U: Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by  
579 BNT162b2 vaccine-elicited human sera. Science 2021:eabg6105.
- 580 [58] Starr TN, Greaney AJ, Dingens AS, Bloom JD: Complete map of SARS-CoV-2 RBD mutations  
581 that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016. bioRxiv  
582 2021:2021.02.17.431683.
- 583 [59] Sabino EC, Buss LF, Carvalho MPS, Prete CA, Jr., Crispim MAE, Fraiji NA, Pereira RHM, Parag  
584 KV, da Silva Peixoto P, Kraemer MUG, Oikawa MK, Salomon T, Cucunuba ZM, Castro MC, de  
585 Souza Santos AA, Nascimento VH, Pereira HS, Ferguson NM, Pybus OG, Kucharski A, Busch MP,  
586 Dye C, Faria NR: Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence. Lancet  
587 2021, 397:452-5.
- 588 [60] Latif AA, Gangavarapu K, Haag E, Matteson N, Mullen JL, Tsueng G, Zeller M, Wu C, Su AI,  
589 Hughes LD, Andersen KG, Biology CfVS: P.2 Lineage Report. outbreak.info, 2021.
- 590 [61] O'Toole Á, Scher E, Underwood A, Jackson B, Hill V, McCrone J, Ruis C, Abu-Dahab K, Taylor  
591 B, Yeats C, Plessis Ld, Aanensen D, Holmes E, Pybus O, Rambaut A: pangolin: lineage assignment  
592 in an emerging pandemic as an epidemiological tool. 2021.
- 593 [62] Latif AA, Gangavarapu K, Haag E, Matteson N, Mullen JL, Tsueng G, Zeller M, Wu C, Su AI,  
594 Hughes LD, Andersen KG, Biology CfVS: B.1.427 Lineage Report. 2021.

- 595 [63] Latif AA, Gangavarapu K, Haag E, Matteson N, Mullen JL, Tsueng G, Zeller M, Wu C, Su AI,  
596 Hughes LD, Andersen KG, Biology CfVS: B.1.429 Lineage Report. outbreak.info, 2021.
- 597 [64] Grabowski F, Kochańczyk M, Lipniacki T: L18F substrain of SARS-CoV-2 VOC-202012/01 is  
598 rapidly spreading in England. medRxiv 2021.
- 599 [65] DeWitt M: Rapid Impact Analysis of B 1.1.7 Variant on the Spread of SARS-CoV-2 in North  
600 Carolina. medRxiv 2021.
- 601 [66] Younes M, Hamze K, Nassar H, Makki M, Ghadar M, Nguewa P, Sater FA: Emergence and  
602 fast spread of B.1.1.7 lineage in Lebanon. medRxiv 2021.
- 603 [67] Vasques Nonaka CK, Miranda Franco M, Gräf T, Almeida Mendes AV, Santana de Aguiar R,  
604 Giovanetti M, Solano de Freitas Souza B: Genomic Evidence of a Sars-Cov-2 Reinfection Case  
605 With E484K Spike Mutation in Brazil. preprintsorg 2021.
- 606 [68] Resende PC, Bezerra JF, Vasconcelos RHTd, Ighor Arantes<sup>3</sup> LA, Mendonça AC, Paixao AC,  
607 Rodrigues ACD, Silva T, Rocha AS, Pauvolid-Corrêa A, Motta FC, Teixeira DLF, Carneiro TFdO,  
608 Neto FPF, Herbster ID, Leite AB, Riediger IN, Debur MdC, Naveca FG, Almeida W, Livorati M,  
609 Bello G, Siqueira MM: Spike E484K mutation in the first SARS-CoV-2 reinfection case confirmed  
610 in Brazil. 2021.
- 611 [69] Wise J: Covid-19: The E484K mutation and the risks it poses. BMJ 2021, 372:n359.
- 612 [70] Liu Z, VanBlargan LA, Bloyet LM, Rothlauf PW, Chen RE, Stumpf S, Zhao H, Errico JM, Theel  
613 ES, Liebeskind MJ, Alford B, Buchser WJ, Ellebedy AH, Fremont DH, Diamond MS, Whelan SPJ:  
614 Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody  
615 neutralization. Cell host & microbe 2021.

616 [71] Wang Z, Schmidt F, Weisblum Y, Muecksch F, Barnes CO, Finkin S, Schaefer-Babajew D,  
617 Cipolla M, Gaebler C, Lieberman JA, Oliveira TY, Yang Z, Abernathy ME, Huey-Tubman KE,  
618 Hurley A, Turroja M, West KA, Gordon K, Millard KG, Ramos V, Silva JD, Xu J, Colbert RA, Patel R,  
619 Dizon J, Unson-O'Brien C, Shimeliovich I, Gazumyan A, Caskey M, Bjorkman PJ, Casellas R,  
620 Hatzioannou T, Bieniasz PD, Nussenzweig MC: mRNA vaccine-elicited antibodies to SARS-CoV-2  
621 and circulating variants. *Nature* 2021.

622 [72] Pater AA, Bosmeny MS, Barkau CL, Ovington KN, Chilamkurthy R, Parasrampur M,  
623 Eddington SB, Yinusa AO, White AA, Metz PE, Sylvain RJ, Hebert MM, Benzinger SW, Sinha K,  
624 Gagnon KT: Emergence and Evolution of a Prevalent New SARS-CoV-2 Variant in the United  
625 States. *bioRxiv* 2021:2021.01.11.426287.

626 [73] Hodcroft EB, Domman DB, Snyder DJ, Oguntuyo K, Van Diest M, Densmore KH, Schwalm  
627 KC, Femling J, Carroll JL, Scott RS, Whyte MM, Edwards MD, Hull NC, Kevil CG, Vanchiere JA, Lee  
628 B, Dinwiddie DL, Cooper VS, Kamil JP: Emergence in late 2020 of multiple lineages of SARS-CoV-  
629 2 Spike protein variants affecting amino acid position 677. *medRxiv* 2021:2021.02.12.21251658.

630 [74] COVID-19 Positive Cumulative Cases. Texas Medical Center COVID-19 Dashboard: TMC,  
631 2021.

632 [75] Vavrek D, Speroni L, Curnow KJ, Oberholzer M, Moeder V, Febbo PG: Genomic surveillance  
633 at scale is required to detect newly emerging strains at an early timepoint. *medRxiv*  
634 2021:2021.01.12.21249613.

635 [76] Burki T: Understanding variants of SARS-CoV-2. *Lancet* 2021, 397:462.

636 [77] White House Briefing Room: President Biden Announces American Rescue Plan. 2021.  
637

638

639


640 **Table 1. Variants of concern or variant of interest identified in the Houston Metropolitan**  
641 **area.**

<b>Variant</b>	<b>No. of Isolates</b>
B.1.1.7	23
B.1.351	2
P.1	4
P.2	39
B.1.429	143
B.1.427	19

642

643






644  
 645 **Figure 1. A:** Schematic showing structural changes present in the spike protein of the major  
 646 SARS.CoV.2 variants identified in the study. S1-NTD, S1 domain-aminoterminal domain; S1-RBD,  
 647 S1 domain-receptor binding domain; S1, S1 domain; S2, S2 domain. **B:** Mapping of important

648 changes onto the cryoEM structure of spike protein. The color scheme matches that used in  
649 panel A. Blue (NTD), purple (RBD), orange (S1), and yellow (S2). Aggregate mutations present in  
650 variants of concern are colored in red when amino acid residues are present in the resolved  
651 structure. Left, side view of SARS-CoV-2 prefusion-stabilized spike. Right, top view. Structure of  
652 PDB 6vsb was used as reference.

653

654



655

656 **Figure 2.** Geospatial distribution for each variant of concern identified in the study.

657 The home address zip code for each patient was used and figures were generated using Tableau

658 version 2020.3.4.